Wildcat Capital Management, LLC 13F holdings, Q3 2024
Holdings as of September 30, 2024 · filings on SEC EDGAR · latest filing →
Wildcat Capital Management, LLC disclosed 7 US equity positions worth $204.6m in its Q3 2024 13F filing. The largest position was ULCC at 73.4% of the reported book, followed by RLX and ALLO.
What did Wildcat Capital Management, LLC own in Q3 2024? Top 7 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs prior |
|---|---|---|---|---|---|---|---|
| 1 | ULCC FRONTIER GROUP HLDGS INC | Industrials | 73.4% | $150.1m | 28,061,351 | – | |
| 2 | RLX RLX TECHNOLOGY INC | Consumer Defensive | 16.0% | $32.7m | 18,046,195 | – | |
| 3 | ALLO ALLOGENE THERAPEUTICS INC | Healthcare | 4.0% | $8.2m | 2,920,787 | – | |
| 4 | URGN UROGEN PHARMA LTD | Healthcare | 3.1% | $6.3m | 495,606 | – | |
| 5 | SKILLZ INC | 2.7% | $5.5m | 979,848 | – | ||
| 6 | KRON1USD KRONOS BIO INC | 0.6% | $1.3m | 1,297,959 | – | ||
| 7 | SILEXION THERAPEUTICS CORP | 0.3% | $535.9k | 1,020,852 | – |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.